• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
ILA
Click for more information
0.00% 6.6¢

ISLAND PHARMACEUTICALS LIMITED - Charts / Financials

Market Cap $8.367M  ! watchlist Created with Sketch. Add to my watchlist
Healthcare

Island Pharmaceuticals Limited is an Australia-based drug repurposing company, focused on... Island Pharmaceuticals Limited is an Australia-based drug repurposing company, focused on areas of need for antiviral therapeutics to address infectious diseases. The Company's lead asset is ISLA-101, a drug, being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases. ISLA-101 has been shown to have activity against all four strains of dengue virus as well as other flaviviruses such as Zika virus, West Nile virus, and Yellow Fever virus, as well as Chikungunya virus. The Company operates a single segment, being research and development activities principally in the geographic regions of Australia and the United States. Its subsidiary is Isla Pharmaceuticals Inc.More

refresh Created with Sketch. REFRESH
Last update - 16.20pm 23/08/2024 (20 minute delay) ?
Day
Open 0.0¢   Day High 0.0¢   Day Low 0.0¢
Daily Volume 0
Bids   Sellers
Number Price Volume   Number Price Volume
3 6.0¢ 48127   2 6.6¢ 153105

Directors & Senior Management

Dr. Paul MacLeman Executive Chairman
Dr. David C. Foster Chief Executive Officer, Managing Director, Executive Director
Mr. Cameron Jones Chief Financial Officer, Company Secretary
Ms. Stephanie Vipond Joint Company Secretary
Mr. Albert Hansen Non-Executive Director
Dr. David L. Brookes Non-Executive Independent Director
Dr. Anna Lavelle Non-Executive Independent Director

Data source: Refinitiv

(20min delay)
Last
6.6¢ 		Change
0.000(0.00%) 		Mkt cap ! $8.367M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0

Buyers (Bids)

No. Vol. Price($)
3 48127 6.0¢
 

Sellers (Offers)

Price($) Vol. No.
6.6¢ 153105 2
View Market Depth
Last trade - 16.12pm 23/08/2024 (20 minute delay) ?

Top Stories

The Rising Tide: How institutional adoption is shaping the future of crypto

This year's institutional demand for Bitcoin supports stability & credibility for the asset class. We look at what's happened since crypto ETFs were approved in the US & what that means for Australian investors.
Dale Gillham's weekly wrap: responding to a weak iron ore price with investing decisions Given the recent fall in iron ore prices below the $100 mark, now might be the time to buy into specialised stocks in the materials sector.
Chariot locks in high-potential drill target at Black Mountain, one of the USA's largest lithium landholdings A southward cluster of outcropping pegmatites on-site Chariot Corporation's (ASX:CC9) flagship Black Mountain hard rock lithium project has led management and geotechs to sign off on a promising future drilling target for the company as exploration on-site gathers pace.
IPH raises $100M to buy up Canadian IP firm Bereskin & Parr IPH Ltd has raised $100 million in an institutional placement to support the acquisition, while also launching a share purchase plan.
Raiden gears up for exploration in final quarter of 2024 Raiden Resources Ltd - which is exploration for a multiplicity of minerals in the Pilbara region of WA - is looking ahead to a busy schedule.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.